Protective Effect of Thiamine Pyrophosphate Against Capecitabine-Induced Liver Injury in Rats
Pharmaceuticals · 19.11.2026 · 19 (11) · 1843
DOI: 10.3390/ph19111843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 19.11.2026. Verfasst von Zeynep Suleyman und 6 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatotoxicity is an adverse effect that may limit the clinical use of capecitabine (CAP). The present study compared the protective effects of thiamine pyrophosphate (TPP) and thiamine against CAP-induced liver injury in rats.
Methods
Twenty-four albino Wistar rats were randomly assigned to four groups (n = 6 per group): healthy control (HG), CAP-treated (CP), TPP + CAP (TPCP), and thiamine + CAP (TCP). The TCP and TPCP groups received thiamine and TPP (20 mg/kg, intraperitoneally), respectively, while the HG and CP groups received 0.9% sodium chloride (NaCl) by oral gavage. Treatments were administered daily, and CAP (200 mg/kg, orally) was given 5 days weekly for 28 days. Hepatic oxidative stress and inflammatory markers, along with serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) activities, were measured. Histopathological injury and the immunoreactivities of cytokines and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were also evaluated.
Results
Compared with HG, CAP increased hepatic MDA and proinflammatory cytokine levels and serum ALT and AST activities, while decreasing tGSH, SOD, and CAT levels (all p < 0.001). TPP attenuated these biochemical alterations more effectively than thiamine (p < 0.001). TPP and thiamine reduced necrosis and hydropic degeneration, and decreased IL-1β, IL-6, TNF-α, and 8-OHdG immunopositivity compared with the CP group (p < 0.001). TPP reduced hepatic immunopositivity more effectively than thiamine (p < 0.001).
Conclusions
Under the tested dosing conditions, TPP provided greater hepatoprotection than thiamine against CAP-induced liver injury in rats; however, further studies are needed to establish its clinical relevance.
Zitieren
APA
Suleyman, Z., Bulut, S., Suleyman, H., Ozkaraca, M., Tebrizi, B., Coban, T. A., & Kandefer, M. Y. (2026). Protective Effect of Thiamine Pyrophosphate Against Capecitabine-Induced Liver Injury in Rats. Pharmaceuticals, 19(11), 1843. https://doi.org/10.3390/ph19111843
Vancouver
Suleyman Z, Bulut S, Suleyman H, Ozkaraca M, Tebrizi B, Coban TA, et al. Protective Effect of Thiamine Pyrophosphate Against Capecitabine-Induced Liver Injury in Rats. Pharmaceuticals. 2026;19(11):1843. doi:10.3390/ph19111843
BibTeX
@article{Suleyman2026,
author = {Suleyman, Zeynep and Bulut, Seval and Suleyman, Halis and Ozkaraca, Mustafa and Tebrizi, Behzat and Coban, Taha Abdulkadir and Kandefer, Meryem Yalvac},
title = {Protective Effect of Thiamine Pyrophosphate Against Capecitabine-Induced Liver Injury in Rats},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1843},
doi = {10.3390/ph19111843}
}
EUVIMED